Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

Dr David Stamler Biotech Showcase Presentation

January 8, 2018 Kerry Rowe

Prana Biotechnology JPM investor presentation_updated

Post navigation

Prana meeting with investors at world’s largest healthcare conference in San Francisco

PBT434 poster presented at the 6th International Multiple System Atrophy Conference

Related Posts

Prana Provides Huntington Disease Trial Update in conjunction with the Huntington Study Group Annual Conference

July 17, 2013

Prana receives $4.8 million R&D Tax Incentive Cash Refund

October 30, 2016

FDA End of Phase 2 Status Update

February 13, 2015

Recent Posts

Alterity raises $35M in placement to international and Australian institutions and sophisticated investors.
XBRL 30 June 2020 filed with the SEC
New data independently confirms and extends laboratory findings and expands safety profile of ATH434
Alterity Therapeutics meeting with US FDA provides development pathway for ATH434
Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065